Mwanzo038290 • KOSDAQ
add
Macrogen Inc
Bei iliyotangulia
₩ 16,150.00
Bei za siku
₩ 16,210.00 - ₩ 16,650.00
Bei za mwaka
₩ 14,920.00 - ₩ 26,700.00
Thamani ya kampuni katika soko
177.01B KRW
Wastani wa hisa zilizouzwa
elfu 62.86
Uwiano wa bei na mapato
-
Mgao wa faida
1.82%
Ubadilishanaji wa msingi
KOSDAQ
Habari za soko
CNBC
saa 1 iliyopita
Stocks to give thanks for this year after big gains. And what to do with
them now
0.38%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (KRW) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 33.00B | 2.20% |
Matumizi ya uendeshaji wa biashara | 13.80B | 4.68% |
Mapato halisi | -3.18B | -60.92% |
Kiwango cha faida halisi | -9.64 | -57.52% |
Mapato kwa kila hisa | — | — |
EBITDA | 2.21B | 47.21% |
Asilimia ya kodi ya mapato | 1.20% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (KRW) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 24.60B | 8.61% |
Jumla ya mali | 274.19B | 3.79% |
Jumla ya dhima | 124.82B | 40.99% |
Jumla ya hisa | 149.37B | — |
hisa zilizosalia | 9.97M | — |
Uwiano wa bei na thamani | 1.09 | — |
Faida inayotokana na mali | -0.54% | — |
Faida inayotokana mtaji | -0.70% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (KRW) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -3.18B | -60.92% |
Pesa kutokana na shughuli | -2.08B | 50.99% |
Pesa kutokana na uwekezaji | -9.57B | -22.48% |
Pesa kutokana na ufadhili | 6.73B | 594.06% |
Mabadiliko halisi ya pesa taslimu | -4.51B | 58.99% |
Mtiririko huru wa pesa | -10.07B | 35.34% |
Kuhusu
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
5 Jun 1997
Tovuti
Wafanyakazi
519
